Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has declared the successful completion of a share placement that has raised USD 250 million. This capital raise has garnered significant attention from international investment firms, with a majority of the final subscribers being long-term and healthcare funds. With this transaction, Akeso’s second in 2024, the company’s cash reserves are projected to reach USD 1.064 billion (RMB 7.5 billion). The company plans to allocate 70% of the financing towards the global clinical development of its internally developed innovative drugs, focusing on its key products in both domestic and international markets.
Established in 2012, Akeso possesses a comprehensive new drug research and development (R&D) platform known as the ACE Platform. It also has an R&D innovation system centered around Tetrabody bispecific antibody development technology, antibody drug conjugate (ADC) technology, mRNA technology, and cell therapy technology. The company’s pipeline comprises over 50 products, spanning therapeutic areas such as oncology, autoimmune disorders, inflammation, and metabolic disorders. Among these, 22 candidate drugs are in clinical stages, with 5 already commercialized and 4 under marketing reviews for 5 indications.- Flcube.com
